

# 190 Antihypertensive Agents



## REFERENCES

1. Vasan RS, Beiser A, Seshadri S, et al: Residual lifetime risk of developing hypertension in middle-aged women and men. *JAMA* 287: 1003, 2002.
2. Bronstein AC, Spyker DA, Cantilena LR Jr, et al; American Association of Poison Control Centers: 2008 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th annual report. *Clin Toxicol (Phila)* 47: 911, 2009.
3. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 289: 2560, 2003. Erratum in: *JAMA* 290: 197, 2003.
4. Juurlink DN, Mamdani MM, Kopp A, et al: Drug-induced lithium toxicity in the elderly: a population-based study. *J Am Geriatr Soc* 52: 794, 2004.
5. Chrischilles E, Rubenstein L, Chao J, et al: Initiation of nonselective alpha-1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. *Clin Ther* 23: 727, 2001.
6. Eddy O, Howell JM: Are one or two dangerous? Clonidine and topical imidazolines exposure in toddlers. *J Emerg Med* 25: 297, 2003.
7. Rangan C, Everson G, Cantrell FL: Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings. *Pediatr Emerg Care* 24: 167, 2008.
8. Mastrianni JA, Abbott FV, Kunos G: Activation of central mu-opioid receptors is involved in clonidine analgesia in rats. *Brain Res* 479: 283, 1989.
9. Seger DL: Clonidine toxicity revisited. *J Toxicol Clin Toxicol* 40: 145, 2002.
10. Sinha Y, Cranswick NE: Clonidine poisoning in children: a recent experience. *J Paediatr Child Health* 40: 678, 2004.
11. Spiller HA, Klein-Schwartz W, Colvin JM, et al: Toxic clonidine ingestion in children. *J Pediatr* 146: 263, 2005.
12. Rapko DA, Rastegar DA: Intentional clonidine patch ingestion by 3 adults in a detoxification unit. *Arch Intern Med* 163: 367, 2003.
13. Horowitz R, Mazor SS, Aks SE, Leikin JB: Accidental clonidine patch ingestion in a child. *Am J Ther* 12: 272, 2005.
14. Anderson RJ, Hart GR, Crumpler CP, Lerman MJ: Clonidine overdose: report of six cases and a review of the literature. *Ann Emerg Med* 10: 107, 1981.
15. Romano MJ, Dinh A: A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder. *Pediatrics* 108: 471, 2001.
16. Artman M, Boerth RC: Clonidine poisoning. A complex problem. *Am J Dis Child* 137: 171, 1983.
17. Kulig K, Duffy J, Rumack BH, et al: Naloxone for treatment of clonidine overdose. *JAMA* 247: 1697, 1982.
18. Gremse DA, Artman M, Boerth RC: Hypertension associated with naloxone treatment for clonidine poisoning. *J Pediatr* 108: 776, 1986.
19. Cook P: Clonidine-induced unconsciousness: reversal with naloxone. *Anaesth Intensive Care* 15: 470, 1987.
20. Banner W Jr, Lund ME, Clawson L: Failure of naloxone to reverse clonidine toxic effect. *Am J Dis Child* 137: 1170, 1983.
21. Worledge SM, Carstairs KC, Dacie JV: Autoimmune haemolytic anaemia associated with methyl dopa therapy. *Lancet* 2(7455): 135, 1966.
22. Thomas A, James BR, Graziano SL: Methyl dopa-induced autoimmune haemolytic anaemia revisited. *N Z Med J* 122: 53, 2009.
23. Bakris GL, Siomos M, Richardson D, et al: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K study group. *Kidney Int* 58: 2084, 2000.
24. Augenstein WL, Kulig KW, Rumack BH: Captopril overdose resulting in hypotension. *JAMA* 259: 3302, 1988.
25. Barr CS, Payne R, Newton RW: Profound prolonged hypotension following captopril overdose. *Postgrad Med J* 67: 953, 1991.
26. Sabroe RA, Black AK: Angiotensin-converting enzyme (ACE) inhibitors and angioedema. *Br J Dermatol* 136: 153, 1997.
27. Vleeming W, van Amsterdam JG, Stricker BH, de Wildt DJ: ACE inhibitor-induced angioedema. Incidence, prevention and management. *Drug Saf* 18: 171, 1998.
28. Byrd JB, Adam A, Brown NJ: Angiotensin-converting enzyme inhibitor-associated angioedema. *Immunol Allergy Clin North Am* 26: 725, 2006.
29. Miller DR, Oliveria SA, Berlowitz DR, et al: Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. *Hypertension* 51: 1624, 2008.
30. Pigman EC, Scott JL: Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors. *Am J Emerg Med* 11: 350, 1993.
31. Malde B, Regalado J, Greenberger PA: Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. *Ann Asthma Allergy Immunol* 98: 57, 2007.
32. Zirkle M, Bhattacharyya N: Predictors of airway intervention in angioedema of the head and neck. *Otolaryngol Head Neck Surg* 123: 240, 2000.
33. Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG: Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. *Ann Allergy Asthma Immunol* 92: 573, 2004.
34. Roberts DS, Mahoney EJ, Hutchinson CT, et al: Analysis of recurrent angiotensin converting enzyme inhibitor-induced angioedema. *Laryngoscope* 118: 2115, 2008.
35. Haymore BR, Yoon J, Mikita CP, et al: Risk of angioedema with angiotensin receptor blockers in patients with prior angioedema associated with angiotensin-converting enzyme inhibitors: a meta-analysis. *Ann Allergy Asthma Immunol* 101: 495, 2008.
36. Smith BA, Ferguson DB: Acute hydralazine overdose: marked ECG abnormalities in a young adult. *Ann Emerg Med* 21: 326, 1992.
37. MacMillan AR, Warshawski FJ, Steinberg RA: Minoxidil overdose. *Chest* 103: 1290, 1993.
38. Farrell SE, Epstein SK: Overdose of Rogaine Extra Strength for Men topical minoxidil preparation. *J Toxicol Clin Toxicol* 37: 781, 1999.
39. Rhoney D, Peacock WF: Intravenous therapy for hypertensive emergencies, part 1. *Am J Health Syst Pharm* 66: 1343, 2009.
40. Rhoney D, Peacock WF: Intravenous therapy for hypertensive emergencies, part 2. *Am J Health Syst Pharm* 66: 1448, 2009.
41. Taylor AA, Shepherd AM, Polvino W, et al: Prolonged fenoldopam infusions in patients with mild to moderate hypertension: pharmacodynamic and pharmacokinetic effects. *Am J Hypertens* 12: 906, 1999.
42. Devlin JW, Seta ML, Kanji S, Somerville AL: Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. *Ann Pharmacother* 38: 755, 2004.

## USEFUL WEB RESOURCES

- American Association of Poison Control Centers—<http://www.aapcc.org/DNN/>
- American Academy of Clinical Toxicology—<http://www.clintox.org/index.cfm>
- European Association of Poisons Centres and Clinical Toxicologists—<http://www.eapcct.org/>
- Asia Pacific Association of Medical Toxicology—<http://www.asiattox.org/>
- South Asian Clinical Toxicology Research Collaboration—<http://www.sactrc.org/>
- TOXBASE: The primary clinical toxicology database of the National Poisons Information Service (free access for UK National Health Service hospital departments and general practices, and National Health Service departments of public health and health protection agency units; available to hospital EDs in Ireland by contract; available to European poison centers whose staff are members of the European Association of Poisons Centres and Clinical Toxicologists; overseas users may be allowed access on payment of a yearly subscription, subject to the approval of the Health Protection Agency)—<http://www.toxbase.org/>